ATE419363T1 - Pharmazeitische impfstoffe gegen hiv - Google Patents

Pharmazeitische impfstoffe gegen hiv

Info

Publication number
ATE419363T1
ATE419363T1 AT04768582T AT04768582T ATE419363T1 AT E419363 T1 ATE419363 T1 AT E419363T1 AT 04768582 T AT04768582 T AT 04768582T AT 04768582 T AT04768582 T AT 04768582T AT E419363 T1 ATE419363 T1 AT E419363T1
Authority
AT
Austria
Prior art keywords
gene product
hiv
pol
gag
nef
Prior art date
Application number
AT04768582T
Other languages
English (en)
Inventor
Joerg Schneider
Original Assignee
Oxxon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322402A external-priority patent/GB0322402D0/en
Priority claimed from GB0322637A external-priority patent/GB0322637D0/en
Application filed by Oxxon Therapeutics Ltd filed Critical Oxxon Therapeutics Ltd
Application granted granted Critical
Publication of ATE419363T1 publication Critical patent/ATE419363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04768582T 2003-09-24 2004-09-23 Pharmazeitische impfstoffe gegen hiv ATE419363T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322402A GB0322402D0 (en) 2003-09-24 2003-09-24 HIV pharmaccines
GB0322637A GB0322637D0 (en) 2003-09-26 2003-09-26 HIV pharmaccines
GB0325011A GB2406336A (en) 2003-09-24 2003-10-27 HIV Pharmaccines

Publications (1)

Publication Number Publication Date
ATE419363T1 true ATE419363T1 (de) 2009-01-15

Family

ID=29738123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768582T ATE419363T1 (de) 2003-09-24 2004-09-23 Pharmazeitische impfstoffe gegen hiv

Country Status (3)

Country Link
AT (1) ATE419363T1 (de)
DE (1) DE602004018817D1 (de)
GB (1) GB2406336A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
BRPI0608798A2 (pt) * 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
EP2302059A1 (de) * 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifikationen der Env-, Gag- und Pol-Protein des Hiv-Virus erhöhen die Immunogenwirkung genetischer Impfstoffe
JP2004508064A (ja) * 2000-09-15 2004-03-18 メルク エンド カムパニー インコーポレーテッド コドン最適化hiv1−gag、pol、nefおよび修飾体を発現する増強された第1世代アデノウイルスワクチン
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Hiv−gagのコドン最適化dnaワクチン

Also Published As

Publication number Publication date
DE602004018817D1 (de) 2009-02-12
GB2406336A (en) 2005-03-30
GB0325011D0 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
Barouch et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates
AU2006283101B2 (en) Polyvalent vaccine
Paris et al. Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
Otten et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins
CN1325512C (zh) Hiv调节/辅助蛋白的融合蛋白
Bansal et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
CY1107818T1 (el) Hiv-1 tat, ή παραγωγα αυτου για προφυλακτικο και θεραπευτικο εμβολιασμο
EA201591213A1 (ru) Вакцины против вируса гепатита b
Karpenko et al. Novel approaches in polyepitope T-cell vaccine development against HIV-1
US8916174B2 (en) HIV DNA vaccine regulated by a caev-derived promoter
Kulkarni et al. Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques
AU2022207422B2 (en) Hiv vaccines and methods of using
von Gegerfelt et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization
AR041764A1 (es) Vacuna basada en polinucleotidos y proteinas derivados del vih
US8765140B2 (en) DNA vaccine compositions with HIV/SIV gene modifications
DE602004018817D1 (de) Pharmazeitische Impfstoffe gegen HIV
MX2021011439A (es) Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente.
Steimer et al. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
WO2022035860A3 (en) Replication-competent adenovirus type 4-hiv env vaccines and their use
US20200368348A1 (en) Compositions and Methods for Promoting Immune Responses to Human Immunodeficiency Virus
JP2006506094A (ja) Rreおよびcteを含む遺伝的構築物および組成物ならびにそれらの使用
Sommerfelt et al. Novel peptide-based HIV-1 immunotherapy
Khan et al. TGF-β1 in Aplysia: Role in Long-Term Changes in the Excitability of Sensory Neurons and Distribution of TβR-II-Like Immunoreactivity
US20120321655A1 (en) Lentivirus vaccine based on the recombinant viral vaccine against yellow fever
Wahren et al. Immune responses to the HIV rev regulatory gene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties